The Colon Club

All you need to know about Biomarkers - Webinar today, September 11
https://fightcolorectalcancer.org/events/need-know-biomarkers/

https://fightcolorectalcancer.org/fight ... 7-webinar/

Thanks. I watched this after the webinar so I didn't get to ask any questions.
The post webinar link changed to here

This webinar leans toward PD-1 research,testing and education, and also recent genetic testing . He also noted that stage 1-3 patients with PD-1 indications may substantially benefit from 1-2 anti-PD1 treatments. He favorably noted the "liquid biopsy" tests in some situations now and a favorable future.

The webinar did have two important, cheap notes: First, that baby aspirin appears to have had a 90% reduction in recurrence in stage 1-3 patients who had PIK3CA mutations. Second, that right sided, Kras-wild CRC patients tended to flunk EGFR (erbitux, vectibix) treatment - right sided is cheap information. Nothing on common biomarkers like CA19-9 for KRAS, BRAF mutants, or targeting cheap drugs like cimetidine, celecoxib, and metformin.

He did acknowledge in the Q&A that biomarkers markedly change with time in metastatic cancer. My wife has had separate peaks in CEA, AFP and CA19-9 that had to be pounded down by multimodal attack. In the last six years, rises in CA19-9 and AFP mostly with changes in supplements and IV C, but prior credit to cimetidine, 5FU, and celecoxib. My wife's current CEA readings have been lower 2.x, near her postsurgical floor values on metronomic immunochemo, ca 1/6th - 1/9th of prior CEA peaks in the first 13 months.

Thanks for posting this JJH and for the synopsis rp1954

I actually happened to be reviewing my husband's Oncopanel this evening and this came in very handy!

rp1954 wrote:Thanks. I watched this after the webinar so I didn't get to ask any questions.
The post webinar link changed to here

This webinar leans toward PD-1 research,testing and education, and also recent genetic testing . He also noted that stage 1-3 patients with PD-1 indications may substantially benefit from 1-2 anti-PD1 treatments. He favorably noted the "liquid biopsy" tests in some situations now and a favorable future.

The webinar did have two important, cheap notes: First, that baby aspirin appears to have had a 90% reduction in recurrence in stage 1-3 patients who had PIK3CA mutations. Second, that right sided, Kras-wild CRC patients tended to flunk EGFR (erbitux, vectibix) treatment - right sided is cheap information. Nothing on common biomarkers like CA19-9 for KRAS, BRAF mutants, or targeting cheap drugs like cimetidine, celecoxib, and metformin.

He did acknowledge in the Q&A that biomarkers markedly change with time in metastatic cancer. My wife has had separate peaks in CEA, AFP and CA19-9 that had to be pounded down by multimodal attack. In the last six years, rises in CA19-9 and AFP mostly with changes in supplements and IV C, but prior credit to cimetidine, 5FU, and celecoxib. My wife's current CEA readings have been lower 2.x, near her postsurgical floor values on metronomic immunochemo, ca 1/6th - 1/9th of prior CEA peaks in the first 13 months.

Thanks for the summary.

Sounds interesting and informative, thanks for posting.

I just wish the presenter named the "better" biomarker detectable in blood tests that can be used to detect recurrence. I realize it's still in development, but I'd like to know what it is.